Is there benefit in dual renin- angiotensin-aldosterone system blockade? No, yes and maybe: A guide for the perplexed

Diabetes and Vascular Disease Research

Volumn 10, Issue 3, 2013, Pages 193-201

  Wong, Jencia ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

blocks; combination; inhibitors; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; VALSARTAN;

ACUTE HEART INFARCTION; ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; CARDIORENAL SYNDROME; CARDIOVASCULAR MORTALITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIASTOLIC HEART FAILURE; DRUG EFFECT; DRUG EFFICACY; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART VENTRICLE FUNCTION; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; KIDNEY INJURY; LOW RISK POPULATION; META ANALYSIS (TOPIC); MICROALBUMINURIA; MONOTHERAPY; MUSCLE HYPERTROPHY; PLASMA RENIN ACTIVITY; PROTEINURIA; QUALITY OF LIFE; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; REVIEW; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE; SYSTOLIC HYPERTENSION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; INDIVIDUALIZED MEDICINE; KIDNEY; PROTEASE INHIBITORS; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84876018863     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112463710     Document Type: Review

References (40)

1. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the management of arterial hypertension. J Hypertens. 2007 ; 25: 1751-1762 (Pubitemid 47356612)
2. Retraction - combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2009 ; 374: 1226
3. Messerli FH. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol. 2009 ; 53: 468-470
4. Members ATF, Dickstein K, Cohen-Solal A, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008 ; 29: 2388-2442
5. Ingelfinger JR. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med. 2008 ; 358: 2503-2505 (Pubitemid 351793025)
6. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006 ; 86: 747-803 (Pubitemid 44033382)
7. Van den Meiracker AH, Man in't, Veld AJ, Admiraal PJJ, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?. J Hypertens. 1992 ; 10: 803-812
8. Ménard J, Campbell DJ, Azizi M, et al. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation. 1997 ; 96: 3072-3078 (Pubitemid 27500110)
9. Doulton TWR, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension. 2005 ; 45: 880-886 (Pubitemid 40628932)
10. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000 ; 321: 1440-1444
11. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 ; 358: 1547-1559
12. Mann JFE, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 372: 547-553
13. Campbell NRC, Khan NA, Hill MD, et al. On behalf of the Canadian Hypertension Education Program. Canadian Hypertension Education Program recommendations: the scientific summary - an annual update. Can J Cardiol. 2009 ; 25: 271-277
14. Moore WV, Fredrickson D, Brenner A, et al. Prevalence of hypertension in patients with type II diabetes in referral versus primary care clinics. J Diabetes Complications. 1998 ; 12: 302-306 (Pubitemid 29029882)
15. Wong J, Molyneaux L, Constantino M, et al. Beyond ONTARGET: angiotensin-converting enzyme inhibition and angiotensin II receptor blockade in combination, a lesser evil in some?. Diabetes Obes Metab. 2010 ; 12: 1072-1078
16. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 ; 345: 861-869
17. Jennings DL, Kalus JS, Coleman CI, et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med. 2007 ; 24: 486-493 (Pubitemid 46669317)
18. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008 ; 148 (1). 30-48 (Pubitemid 351688350)
19. Messerli FH, Staessen JA, Zannad F. Of fads, fashion, surrogate endpoints and dual RAS blockade. Eur Heart J. 2010 ; 31: 2205-2208
20. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009 ; 361: 40-51
21. Lattanzio MR, Weir MR. Have we fallen off target with concerns surrounding dual RAAS blockade. Kidney Int. 2010 ; 78: 539-545
22. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med. 1995 ; 123: 754-762
23. Fried LF, Duckworth W, Zhang JH, et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol. 2009 ; 4: 361-368
24. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 ; 349: 1893-1906 (Pubitemid 37409706)
25. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol. 2000 ; 32: 865-879 (Pubitemid 30663097)
26. Krum H, Carson P, Farsang C, et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail. 2004 ; 6: 937-945 (Pubitemid 39536310)
27. McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003 ; 362: 767-771 (Pubitemid 37093916)
28. Yarows S, Oparil S, Patel S, et al. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther. 2008 ; 25: 1288-1302
29. Solomon SD, Hee Shin S, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011 ; 32: 1227-1234
30. Parving H-H, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008 ; 358: 2433-2446 (Pubitemid 351793017)
31. Parving H-H, Brenner BM, McMurray JJV, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009 ; 24: 1663-1671
32. Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail. 2011 ; 13: 107-114
33. Harel Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012 ; 344: e42
34. McMurray JJV, Abraham WT, Dickstein K, et al. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail. 2012 ; 14: 341-343
35. Jansen PM, Danser AJ, Imholz BP, et al. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009 ; 27: 680-691
36. Bomback AS, Kshirsagar AV, Amamoo MA, et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008 ; 51: 199-211
37. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 ; 348: 1309-1321 (Pubitemid 36384098)
38. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999 ; 341: 709-717 (Pubitemid 29407370)
39. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008 ; 372: 1394-1402
40. KhatibRJosephPBrielM. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. Int J Cardiol. Epub ahead of print 16March2012. http://dx.doi.org/10.1016/j.ijcard. 2012.02.009.